European Confederation of Medical Mycology
Confédération Européenne de Mycologie Médicale

Observational study to determine the rate of occurrence of invasive mould disease and treatment outcomes in at-risk patients: a European prospective invasive mould disease audit (PIMDA).

ECMM is seeking participation from European hospitals with haematology units and/or transplant centres that frequently treat patients for AML/MDS, or recipients of an allogeneic HSCT, or both, to take part in an observational study to determine the rate of occurrence of invasive mould disease (IMD) and treatment outcomes in at-risk patients.

Claudio Viscoli, University of Genova, Genova, Italy
 

O. Marchetti, Infectious Disease Service, Dept. of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland

Maiken Cavling Arendrup, Unit of Mycology and Parasitology, Staten Serum Institut

Chris Kibbler, University College London, And Royal Free Hospital, London, UK

Cornelia Lass-Flörl, Medical University Innsbruck

George Petrikkos, National and Kapodistrian University of Athens, Greece

Francesco Barchiesi, Dipartimento di Scienze Biomediche, Clinica di Malattie infettive, Università Politecnica delle Marche - Italy

Andrea Novelli, Dipartimento di Farmacologia Preclinica e Clinica, Università degli Studi di Firenze
 

Georg Maschmeyer, Dept. of Hematology, Oncology & Palliative Care,
Klinikum Ernst von Bergmann, Potsdam, Germany